Nadine Rouphael MD
Overview
Dr. Nadine Rouphael (MD) is the Sumner E. Thompson, III Distinguished Professor of Vaccinology and Infectious Diseases at Emory University in Atlanta, USA. She graduated from Saint Joseph University School of Medicine in Lebanon (2001). She completed her internal medicine residency (2005) and infectious diseases fellowship (2008) at Emory University. She serves as the executive director of the Hope Clinic, the clinical arm of the Emory Vaccine Center and the Emory principal investigator for the NIH funded Vaccine Treatment and Evaluation Unit (VTEU) and the co Clinical Core principal investigator for NIH funded Stanford Human Immunology Project Consortium (HIPC). She has served as the national chair/co-chair as well as overall PI/site PI of 75 clinical studies and an investigator on more than 200 studies. She has interest in antimicrobial resistance, vaccine clinical trials (pandemic influenza, Zika, Ebola, SARS-CoV2), vaccine delivery methods (NIH funded phase 1 trial on microneedle influenza vaccine patch where a first in human dissolvable patch was shown to be safe, immunogenic and preferred to the traditional needle and syringe), translational research on innate immunity and systems biology (using vaccines as way to probe the immune system and one of the first to show an association between antibiotic use and decrease immunogenicity), immune aging and correlates of protection. She has published more than 180 peer reviewed publications and has received many awards. She is currently the associate editor for Clinical Infectious Diseases for the Vaccine section. She is passionate about mentoring the next generation of physician scientists and serves as Co-Director of the Stimulating Access to Research in Residency (StARR) R38 Program and the Director of the T32 vaccinology grant.
Academic Appointment
- Sumner E. Thompson, III Distinguished Professor of Vaccinology and Infectious Diseases, Emory University School of Medicine
- Tenured Professor of Medicine, Emory University School of Medicine
- Professor of Medicine, Emory University School of Medicine
- Senior Physician, Emory University School of Medicine
- Investigator, Hope Clinic of the Emory Vaccine Center
Education
Degrees
- M.S. from Jean Moulin University
- M.S. from Saint Joseph University School of Medicine
- M.D. from Saint Joseph University School of Medicine
Research
Focus
-
Vaccine Clinical Trials
My research focuses on: 1) Correlates of protection for encapsulated bacteria 2) Innate immunity to vaccines through system biology approaches 3) Immune senescence 4) Novel methods for vaccine delivery and human challenges
Publications
-
Antibiotic-induced gut microbiome perturbation alters the immune responses to the rabies vaccine.
Cell Host Microbe
04/15/2025 Authors: Feng Y; de Jong SE; Oliveira APBN; Samaha H; Yang F; Hu M; Wang Y; Beydoun N; Xie X; Zhang H -
Altered baseline immunological state and impaired immune response to SARS-CoV-2 mRNA vaccination in lung transplant recipients.
Cell Rep Med Volume: 6 Page(s): 102050
04/15/2025 Authors: Hu M; Oliveira APBN; Fang Z; Feng Y; Miranda M; Kowli S; Arunachalam PS; Vasudevan G; Hui HS-Y; Grifoni A -
Fgl2 regulates FcRIIB+CD8+ T cell responses during infection.
JCI Insight Volume: 10
04/08/2025 Authors: Morris AB; Adelman MW; Bennion KB; Martinez CD; McCook K-M; Woodworth MH; Langelier CR; Rouphael N; Scharer CD; Maier CL -
Efficacy and Durability of Immune Response After Receipt of Hepatitis A Vaccine in People With Human Immunodeficiency Virus.
Open Forum Infect Dis Volume: 12 Page(s): ofaf143
04/01/2025 Authors: Kazzi B; Naji A; Dib SM; Khalil L; Tandon Wimalasana S; Saint-Victor D; Ofotokun I; Rouphael N -
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone or Flublok) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45years of age.
Vaccine Volume: 54 Page(s): 126991
03/18/2025 Authors: Hegmann TE; Walter EB; Smith MJ; Campbell J; El Sahly HM; Whitaker JA; Creech CB; Ustyugova IV; Goncalvez AP; Pandey A -
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant.
Lancet Infect Dis Volume: 25 Page(s): e122 - e123
03/01/2025 Authors: Suthar MS; Manning KE; Ellis ML; Jain S; Bechnak K; Vander Velden J; Laboune F; Henry AR; Godbole S; Kim S -
Transcriptomic Biomarkers Associated With Microbiological Etiology and Disease Severity in Childhood Pneumonia.
J Infect Dis Volume: 231 Page(s): e277 - e289
02/20/2025 Authors: Williams DJ; Gautam S; Creech CB; Jimenez N; Anderson EJ; Bosinger SE; Grimes T; Arnold SR; McCullers JA; Goll J -
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.
Vaccine Volume: 47 Page(s): 126689
02/15/2025 Authors: El Sahly HM; Anderson EJ; Jackson LA; Neuzil KM; Atmar RL; Bernstein DI; Chen WH; Creech CB; Frey SE; Goepfert P -
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Clin Infect Dis Volume: 80 Page(s): 223 - 227
02/05/2025 Authors: Fong Y; Dang L; Zhang B; Fintzi J; Chen S; Wang J; Rouphael NG; Branche AR; Diemert DJ; Falsey AR -
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.
Nat Commun Volume: 16 Page(s): 759
01/17/2025 Authors: Zhang B; Fong Y; Dang L; Fintzi J; Chen S; Wang J; Rouphael NG; Branche AR; Diemert DJ; Falsey AR